Search

Christopher Bieniarz Phones & Addresses

  • Paradise Valley, AZ
  • 2462 Calle Sin Controversia, Tucson, AZ 85718 (520) 797-0577
  • 2263 Quiet Canyon Dr, Tucson, AZ 85718 (520) 877-2293 (520) 797-0577
  • Oro Valley, AZ
  • 718 Old Trail Rd, Highland Park, IL 60035 (847) 432-2156
  • Pima, AZ
  • 718 Old Trail Rd, Highland Park, IL 60035

Work

Position: Production Occupations

Education

Degree: Graduate or professional degree

Resumes

Resumes

Christopher Bieniarz Photo 1

Senior Director, Chemistry And Innovation Technologies

View page
Location:
Tucson, AZ
Industry:
Biotechnology
Work:
Ventana Medical Systems
Senior Director, Chemistry and Innovation Technologies

Vmsi (Veterans Management Services, Inc.)
Senior Director
Christopher Bieniarz Photo 2

Senior Director

View page
Location:
Tucson, AZ
Industry:
Biotechnology
Work:
Ventana Medical Systems
Senior Director

Publications

Us Patents

Fluoroether Compositions And Methods For Inhibiting Their Degradation In The Presence Of A Lewis Acid

View page
US Patent:
6444859, Sep 3, 2002
Filed:
Aug 8, 2001
Appl. No.:
09/924573
Inventors:
Christopher Bieniarz - Highland Park IL
Steve H. Chang - Gurnee IL
Keith R. Cromack - Lake Bluff IL
Shuyen L. Huang - Riverwoods IL
Toshikazu Kawai - Saitama, JP
Manami Kobayashi - Saitama, JP
David Loffredo - Elmnurst IL
Rajagopalan Raghavan - Grayslake IL
Earl R. Speicher - Buffalo Grove IL
Honorate A. Stelmach - Lake Forest IL
Assignee:
Abbott Laboratories - Abbott Park IL
Central Glass Company LTD - Tokyo
International Classification:
C07C 4312
US Classification:
568683, 514722, 514816
Abstract:
The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Polymeric Compositions And A Method Of Making The Same

View page
US Patent:
6503528, Jan 7, 2003
Filed:
Nov 19, 1999
Appl. No.:
09/444478
Inventors:
Christopher Bieniarz - Highland Park IL
Amy Jo Sanders - Massillon OH
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61F 202
US Classification:
424426, 5147723
Abstract:
The invention relates to a bioerodible polymeric composition, a method of making such a composition, and a controlled delivery device comprising the composition.

Fluoroether Compositions And Methods For Inhibiting Their Degradation In The Presence Of A Lewis Acid

View page
US Patent:
6677492, Jan 13, 2004
Filed:
Jul 3, 2002
Appl. No.:
10/190271
Inventors:
Christopher Bieniarz - Highland Park IL
Steve H. Chang - Gurnee IL
Keith R. Cromack - Lake Bluff IL
Shuyen L. Huang - Riverwoods IL
Toshikazu Kawai - Saitama, JP
Manami Kobayashi - Saitama, JP
David Loffredo - Elmhurst IL
Rajagopalan Raghavan - Grayslake IL
Earl R. Speicher - Buffalo Grove IL
Honorats A. Stelmach - Lake Forest IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
C07C 4312
US Classification:
568683, 514722, 514816
Abstract:
The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Microwave Mediated Synthesis Of Nucleic Acid Probes

View page
US Patent:
7541455, Jun 2, 2009
Filed:
Dec 21, 2004
Appl. No.:
11/018897
Inventors:
Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Jerome W. Kosmeder - Tucson AZ, US
Mark Lefever - Tucson AZ, US
Assignee:
Ventana Medical Systems, Inc. - Tucson AZ
International Classification:
C07H 21/02
C07H 21/04
C12Q 1/68
US Classification:
536 2626, 536 2623, 536 268, 435 6
Abstract:
A method for preparing a nucleic acid probe is provided. The method comprises forming an activated cytosine or cytidine by a bisulfite catalyzed reaction; and covalently linking a reporter molecule to the activated cytosine or cytidine, wherein said activating step, said covalently linking step, or both are conducted in the presence of microwave energy. Also provided by the invention are nucleic acid probes.

Enzyme-Catalyzed Metal Deposition For The Enhanced In Situ Detection Of Immunohistochemical Epitopes And Nucleic Acid Sequences

View page
US Patent:
7632652, Dec 15, 2009
Filed:
Jun 24, 2004
Appl. No.:
10/877919
Inventors:
Christopher Bieniarz - Tucson AZ, US
Casey A. Kernag - Tucson AZ, US
Jerome W. Kosmeder - Tucson AZ, US
Paula Rodgers - Tucson AZ, US
Jennifer Wong - Tucson AZ, US
Assignee:
Ventana Medical Systems, Inc. - Tucson AZ
International Classification:
C12Q 1/42
C12Q 1/44
C12Q 1/54
C12Q 1/68
G01N 33/53
G01N 33/543
G01N 33/567
US Classification:
435 791, 435 6, 435 71, 435 14, 435 19, 435 21, 435 405, 435 4052, 435188, 436503, 436518, 436164, 549218, 549398, 558190
Abstract:
The invention is directed to novel compositions of matter and methods of detecting in situ an immunohistochemical epitope or nucleic acid sequence of interest in a biological sample comprising binding an enzyme-labeled conjugate molecule to the epitope or sequence of interest in the presence of a redox-inactive reductive species and a soluble metal ion, thereby facilitating the reduction of the metal ion to a metal atom at or about the point where the enzyme is anchored. Novel phosphate derivatives of reducing agents are described that when exposed to a phosphatase are activated to their reducing form, thereby reducing metal ions to insoluble metal.

Enzyme-Catalyzed Metal Deposition For The Enhanced Detection Of Analytes Of Interest

View page
US Patent:
7642064, Jan 5, 2010
Filed:
Dec 20, 2004
Appl. No.:
11/015646
Inventors:
Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Assignee:
Ventana Medical Systems, Inc. - Tucson AZ
International Classification:
C12Q 1/42
C12Q 1/44
C12Q 1/54
G01N 33/53
G01N 33/543
G01N 33/544
G01N 33/551
US Classification:
435 794, 435 71, 435 791, 435 14, 435 19, 435 21, 435188, 436503, 436514, 436518, 436524, 436528, 436164
Abstract:
The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.

Method For Quantifying Biomolecules Conjugated To A Nanoparticle

View page
US Patent:
7682789, Mar 23, 2010
Filed:
May 4, 2007
Appl. No.:
11/800360
Inventors:
Xiao-Bo Chen - Tucson AZ, US
Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Assignee:
Ventana Medical Systems, Inc. - Tucson AZ
International Classification:
C12Q 1/68
G01N 33/53
C07K 14/00
C07H 21/00
C07H 21/02
C07H 21/04
US Classification:
435 6, 435 71, 530350, 536 221, 536 231, 536 243
Abstract:
Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve.

Haptens, Hapten Conjugates, Compositions Thereof And Method For Their Preparation And Use

View page
US Patent:
7695929, Apr 13, 2010
Filed:
Nov 1, 2007
Appl. No.:
11/982627
Inventors:
Jerome W. Kosmeder - Tucson AZ, US
Mark Lefever - Tucson AZ, US
Donald Johnson - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Zhanna Zhilina - Oro Valley AZ, US
Christopher Bieniarz - Tucson AZ, US
Assignee:
Ventana Medical Systems, Inc. - Tucson AZ
International Classification:
G01N 33/53
C07K 16/00
US Classification:
435 794, 435 71, 435 792, 435961, 5303898, 5303913, 530807
Abstract:
A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
Christopher J Bieniarz from Paradise Valley, AZ, age ~79 Get Report